Higher Risk Classes in New Zealand: Class IIa, IIb, III and AIMD

Regulatory information verified as of 29 October 2026

1. Key takeaways

The New Zealand risk ordering sits in regulation 11 of SR 2003/325: five classes, Class I the lowest, Class IIa and Class IIb progressively higher, Class III and AIMD (Active Implantable Medical Device) the highest. The class of a device is determined by regulation 12 — the result of the 22 Schedule 2 rules applied under regulation 13.

Medium and high risk classes reduce to three escalation factors: the site of contact (heart, central circulatory or central nervous system contact), the mode of action (biological effects, absorption, chemical change in the body, ionising radiation or medicine administration), and the duration (per rule 1, under 60 minutes transient, 60 minutes to 30 days short-term, over 30 days long-term).

Regulation 13(7): where 2 or more rules apply by intended purpose, the device takes the highest of the resulting classes — scan the whole table, not stop at the first hit.

One added duty: under reg 5(2), only non-exempt Class III and AIMD devices also record a unique product identifier (UPI) in WAND; Class I, IIa and IIb have no such requirement. Under reg 5(4) the UPI is the trade name or brand name, which the Director-General may require combined with another product identification form.

The system’s origin: New Zealand has no pre-market approval, no registration certificates, no Medsafe technical review; WAND is a mandatory post-arrival notification database, not a pre-market gate. Class III or AIMD brings no approval — only higher record precision and heavier Sponsor responsibility.

2. Legal basis

The table below lists the sources verified and the provisions relied on.

3. Expert insights

Insight 1: the reg 11 ordering is an operative rule, not a ranking table.

Reg 11(2) states Class I lowest, IIa and IIb progressively higher, III and AIMD highest. Its function is not merely descriptive: it determines how reg 13(7)’s take-the-highest rule executes and to which two classes the reg 5(2) duty applies. AIMD and Class III sit together at the top, but AIMD is determined by the features of being active and implanted, not by risk cumulation.

Insight 2: Class IIa — entry class of the medium-to-low range.

Typical IIa situations: non-invasive devices channelling or storing blood or body fluids entering the body, storing organs or tissues for implantation, or connecting to Class IIa-or-above active devices; altering blood composition by filtration, centrifugation or gas or heat exchange; injured-skin contact limited to general wound management; body-orifice invasion for short-term use (fallbacks for oral-to-pharynx, ear-canal-to-eardrum and nasal sites); the general case of active therapeutic (administering or exchanging energy) and diagnostic devices; the general case of active devices administering or removing substances; non-active diagnostic X-ray imaging recorders.

Insight 3: Class IIb — potentially hazardous is the key phrase.

Schedule 2 uses potentially hazardous as the switch from IIa to IIb in several places: therapeutic energy administered or exchanged in a potentially hazardous way; diagnostic monitoring of vital physiological parameters whose variation could cause immediate danger; ionising radiation for interventional radiology; substances administered or removed in a potentially hazardous manner. Also pointing to IIb: non-invasive devices altering the biological or chemical composition of blood or other liquids; body-orifice invasion for long-term use; long-term surgically invasive devices; implantable devices (dental ones reduced to IIa); contraceptive and STD-prevention devices; contact lens and device disinfecting products; blood bags; devices mainly for dermis wounds needing second-intention healing.

Insight 4: Class III — terminus of the three escalation factors.

Typical Class III situations: devices incorporating, as an integral part, a substance that constitutes a medicinal product on its own; devices with microbial or recombinant-derived materials beyond non-viable animal-derived ones, or non-viable animal-derived materials contacting more than intact skin; implantable or long-term invasive devices for contraception or STD prevention; surgically invasive devices directly contacting the heart, central circulatory or central nervous system; long-term surgically invasive and implantable devices with biological effects, wholly or mainly absorbed, undergoing chemical change in the body, or administering medicines; implantable accessories of AIMDs and active devices controlling, monitoring or directly influencing AIMD performance; breast implants.

Insight 5: AIMD and the Class III spillover.

Rule 20 of Schedule 2 is the sole AIMD entry: an active implantable device is Class AIMD. The same rule pulls two adjacent categories to Class III — implantable accessories of AIMDs, and active devices controlling, monitoring or directly influencing AIMD performance. Typically, an implantable pacemaker or infusion pump is an AIMD; its implantable electrode leads are Class III, and external programmers controlling or monitoring the implant likewise Class III.

Insight 6: responsibility and the boundary of foreign conclusions.

Medsafe makes no determination on submitted classifications; where a device cannot be classified, consult the manufacturer; responsibility rests with the Sponsor (New Zealand sponsor) and the manufacturer. EU MDR or Australian TGA conclusions cannot be applied directly — the official Medsafe text reads: “Recent or planned changes to risk classification systems in Europe and Australia mean there are now differences between risk classifications in those regulatory regimes and New Zealand.”

GRZAN notes that once Class III or AIMD is set, beyond the reg 5(2) UPI duty, loop back to reg 5(3) and reg 5(5): grouping applies only to Class I, IIa and IIb; Class III and AIMD must be entered item by item. The origin bears repeating: no pre-market approval, no registration certificates, no Medsafe technical review; a medium or high classification produces no approval or certificate — only WAND record fields and the intensity of subsequent compliance.

4. Practical recommendations

• Set the three escalation factors as independent fields; the conclusion must derive from them, never from experience.
• Document the potentially hazardous clauses item by item: devices involving energy administration, ionising radiation, medicine administration or vital-parameter monitoring must state whether a potentially hazardous manner exists and why — the most challenged IIa/IIb boundary.
• Duration must be fixed in writing into one of rule 1’s three bands (60 minutes / 30 days); vague wording such as short-term use is not accepted.
• Once Class III or AIMD is set, start the UPI request and abandon the reg 5(3) grouping route, scheduling entry item by item (practical estimate).
• Apply the 7 principles of reg 13 throughout, especially (5) software follows its device and (7) take the highest.
• Do not carry over EU MDR or TGA conclusions; return first to the 22 local rules of Schedule 2. Medsafe has noted the European and Australian changes create differences; medicines-incorporating devices, animal-derived materials and disinfecting products misalign especially easily (practical estimate).

5. Verification checklist

• □ The 5-class ordering of reg 11 and the device’s position confirmed.
• □ The 22 Schedule 2 rules fully scanned, without early termination.
• □ The three escalation factors completed item by item, traceable to evidence.
• □ Duration placed in one of the three statutory bands (60 minutes / 30 days).
• □ The potentially hazardous clauses documented with reasons, clause by clause.
• □ Highest class taken under reg 13(7) where multiple rules were hit.
• □ Combination devices classified separately (reg 13(3)), accessories separately (reg 13(4)), software sharing its device’s class (reg 13(5)).
• □ EU MDR and Australian TGA conclusions not applied directly.
• □ For Class III or AIMD conclusions, the UPI request has started and entry is item by item.
• □ The conclusion is confirmed in writing by the manufacturer, not from foreign conclusions.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the New Zealand market. Our team prepares WAND-compliant evidence dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com